Kintara Therapeutics, Inc. (KTRA)
| Market Cap | 574.57K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -13.20M |
| Shares Out | 3.39M |
| EPS (ttm) | -7.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 123,840,728 |
| Open | 0.289 |
| Previous Close | 0.193 |
| Day's Range | 0.165 - 0.295 |
| 52-Week Range | 0.160 - 9.000 |
| Beta | 0.86 |
| Analysts | Strong Buy |
| Price Target | 14.00 (+8,154.72%) |
| Earnings Date | Feb 13, 2024 |
About KTRA
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous m... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for KTRA stock is "Strong Buy" and the 12-month stock price forecast is $14.0.
News
Top 3 Health Care Stocks That Are Preparing To Pump This Month - Durect (NASDAQ:DRRX), Aadi Bioscience (NASDAQ:AADI)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Kintara Therapeutics Announces Review of Strategic Alternatives
- Ladenburg Thalmann Hired as Financial advisor - SAN DIEGO , Dec. 7, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused o...
Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement
SAN DIEGO , Dec. 5, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...
Top 5 Health Care Stocks That Could Blast Off In December - DBV Technologies (NASDAQ:DBVT), Cigna Group (NYSE:CI)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Kintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate Update
SAN DIEGO , Nov. 13, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...
Kintara Therapeutics Announces Preliminary Topline Results From GBM AGILE Study
- VAL-083 Did Not Perform Better Than Current Standards of Care - - Company Suspending Development of VAL-083, Shifting Focus to REM-001 Program and Other Strategic Opportunities - SAN DIEGO , Oct. 31...
Kintara Therapeutics to Present at the 8th Annual Dawson James Small Cap Growth Conference
SAN DIEGO , Oct. 11, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...
Kintara Therapeutics to Present at the LD Micro Main Event XVI Conference
SAN DIEGO , Oct. 2, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...
Kintara Therapeutics Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual Meeting
SAN DIEGO , Sept. 25, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor therapies, ...
Kintara Therapeutics Announces Fiscal 2023 Year Financial Results and Provides Corporate Update
SAN DIEGO , Sept. 18, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer ther...
Kintara Therapeutics to Present at the 2023 European Association for Neuro-Oncology Annual Meeting
SAN DIEGO , Sept. 5, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer ther...
Kintara Therapeutics to Host Virtual KOL Event on VAL-083, A Potential First-in-Class Small Molecule Chemotherapeutic for Glioblastoma, on August 21, 2023
SAN DIEGO , Aug. 17, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...
Kintara Therapeutics to Present at the Emerging Growth Conference
SAN DIEGO , Aug. 9, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...
Kintara Therapeutics to Participate in the Fifth Annual Glioblastoma Awareness Day in Washington, D.C.
SAN DIEGO , July 19, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...
Kintara Therapeutics Awarded $2.0 Million National Institutes of Health SBIR Grant to Support the Clinical Development of REM-001
SAN DIEGO , June 28, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...
Kintara Therapeutics to Participate in the Maxim Group Virtual Healthcare Conference
SAN DIEGO , June 16, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...
Kintara Therapeutics to Commemorate National Brain Tumor Awareness Month with Ringing the Bell at Nasdaq Closing Along with Global Coalition for Adaptive Research and the National Brain Tumor Society
SAN DIEGO , May 19, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...
Kintara Therapeutics Announces Fiscal 2023 Third Quarter Financial Results and Provides Corporate Update
SAN DIEGO , May 11, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...
Kintara Therapeutics to Present at the Sidoti Micro-Cap Virtual Conference
SAN DIEGO , May 8, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therap...
Kintara Therapeutics to Present at the Aegis Capital Virtual Conference
SAN DIEGO , May 1, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapi...
Kintara Therapeutics Announces Data Presentation at the 2023 American Association for Cancer Research Annual Meeting
SAN DIEGO , April 14, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer ther...
Kintara Therapeutics to Present Two Posters at the 2023 American Association for Cancer Research Annual Meeting
SAN DIEGO , March 15, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer ther...
Kintara Therapeutics Scheduled to Present at Two Conferences the Week of March 13, 2023
-35th Annual ROTH Conference, March 12-14, 2023 – -4th Annual Glioblastoma Drug Development Summit, March 14-16, 2023- SAN DIEGO , March 10, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KT...
Kintara Therapeutics Announces Fiscal 2023 Second Quarter Financial Results and Provides Corporate Update
SAN DIEGO , Feb. 14, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...
Kintara Therapeutics to Present at the 2023 BIO CEO & Investor Conference
SAN DIEGO , Jan. 30, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer thera...